Acadia Pharmaceuticals vs PTC Therapeutics
PTC Therapeutics is the larger business, with $1.73bn of revenue in fiscal 2025 against $1.07bn for Acadia Pharmaceuticals (1.6 times as much). PTC Therapeutics grew faster (114.5% against 11.9%). PTC Therapeutics kept more of each dollar of sales as profit: a net margin of 39.4% against 36.5%.
| Latest fiscal year | Acadia PharmaceuticalsACAD, 2025 | PTC TherapeuticsPTCT, 2025 |
|---|---|---|
| Revenue | $1.07bn | $1.73bn |
| Revenue growth | 11.9% | 114.5% |
| Net income | $391m | $683m |
| Operating margin | 9.8% | 50.1% |
| Net margin | 36.5% | 39.4% |
| Return on equity | 39.9% | — |
| Free cash flow | $105m | $702m |
| Cash | $178m | $985m |
| Total debt | $0 | $573m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 798 | — |
| Market value | $3.55bn | $5.66bn |
| Price vs our value range | — | Above our value range |
| Moat score | 44 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 203 sales |